Ornithine transcarbamylase (OTC) deficiency is a genetic disorder that affects the body’s ability to process nitrogen. The treatment market for OTC deficiency is dominated by pharmaceutical and biotechnology companies offering enzyme replacement therapy (ERT) products. ERT involves the administration of functional OTC enzyme to compensate for the deficiency and prevent the buildup of toxic substances. Currently, the only approved ERT for OTC deficiency is Lumizyme, developed by Sanofi Genzyme. Other companies, such as Pfizer and Eisai, are developing new treatments for OTC deficiency, including new forms of ERT and gene therapy. The global OTC deficiency treatment market is expected to grow due to the increasing prevalence of OTC deficiency and the growing demand for effective treatments.
Ornithine transcarbamylase (OTC) deficiency therapy market is projected to grow as the number of people with this deficiency rises. Fact.MR predicts that the worldwide OTC deficiency treatment market will approach the billion dollar mark by 2030, growing at a constant CAGR over the forecast period of 2020–2030.
Download Free Sample Copy of this Report – https://www.factmr.com/connectus/sample?flag=S&rep_id=5204
OTC Deficiency Treatment Market – Segmentation
- Dietary Supplements
Route of Administration
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- North America
- Asia Pacific
- Latin America
- Middle East & Africa
Get Customization on this Report for Specific Research Solutions – https://www.factmr.com/connectus/sample?flag=RC&rep_id=5204
Key Takeaways from OTC Deficiency Treatment Market Report
- North America is slated to dominate the global ornithine transcarbamylase deficiency treatment market, with Asia Pacific is following closely.
- By product, Ravicti OCT deficiency treatment drugs are likely to pivot market growth.
- Orally administrable drugs will enjoy high popularity, owing to ease of ingestion and minimal trauma.
- Hospital pharmacies will be the primary point-of-sale for OCT deficiency treatment drugs.
- The threat of COVID-19 infection and fatality increases for patients suffering from other co-morbidities, heightening the need for innovation in vaccines, which is giving imputes to the growth of the ornithine transcarbamylase deficiency treatment market.
OTC Deficiency Treatment Market: Competition Analysis
The global ornithine transcarbamylase deficiency treatment market is interspersed with the presence of several renowned pharmaceutical companies. Product launches, acquisitions, and strategic collaborations form a part and parcel of prominent players’ key consolidation strategies.
- In February 2010, Abbott Laboratories acquired Solvay S.A for US$ 6.2 billion. This led to the company’s pharmaceutical products portfolio expansion and presence in key emerging markets.
- In 2017, Mead Johnson Nutrition entered a merger agreement with Reckitt Benckiser, thereby allowing the company to market its nutrition enhancing products on a much wider scale by tapping into a much larger customer base. Some of its products include Enfamil®, Enfagrow®, and Choco Milk®, among others.
- With respect to product development, Arcturus Technologies is working on multiple OTC deficiency treatment drugs. It currently markets LUNAR® delivery based Messenger RNA (mRNA) infused medicines to treat protein deficiency diseases such as UCDs.
For in-depth competitive analysis, Buy Now – https://www.factmr.com/checkout/5204
More Valuable Insights on Ornithine Transcarbamylase Deficiency Treatment Market
In its latest release, Fact.MR provides a fair study of the market for ornithine transcarbamylase deficiency treatments, including historical demand data (from 2015 to 2019) and projections for the years 2020 to 2030. The report provides crucial information on the distribution channels (hospital pharmacies, retail pharmacies, and internet pharmacies) and product categories (buphenyl, ravicti, ammonul, dietary supplements, and others) across five key areas.
US Sales Office:
11140 Rockville Pike
Rockville, MD 20852
Tel: +1 (628) 251-1583